DSpace university logo mark
Advanced Search
Japanese | English 

NAOSITE : Nagasaki University's Academic Output SITE > School of Medicine > Articles in academic journal >

Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules


File Description SizeFormat
ARD71_1820.pdf277.07 kBAdobe PDFView/Open

Title: Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules
Authors: Sakai, Ryoko / Tanaka, Michi / Nanki, Toshihiro / Watanabe, Kaori / Yamazaki, Hayato / Koike, Ryuji / Nagasawa, Hayato / Amano, Koichi / Saito, Kazuyoshi / Tanaka, Yoshiya / Ito, Satoshi / Sumida, Takayuki / Ihata, Atsushi / Ishigatsubo, Yoshiaki / Atsumi, Tatsuya / Koike, Takao / Nakajima, Atsuo / Tamura, Naoto / Fujii, Takao / Dobashi, Hiroaki / Tohma, Shigeto / Sugihara, Takahiko / Ueki, Yukitaka / Hashiramoto, Akira / Kawakami, Atsushi / Hagino, Noboru / Miyasaka, Nobuyuki / Harigai, Masayoshi
Issue Date: Nov-2012
Publisher: BMJ Publishing Group
Citation: Annals of the Rheumatic Diseases, 71(11), pp.1820-1826; 2012
Abstract: Objective: To compare reasons for discontinuation and drug retention rates per reason among anticytokine therapies, infliximab, etanercept and tocilizumab, and the risk of discontinuation of biological agents due to adverse events (AE) in patients with rheumatoid arthritis (RA). Method: This prospective cohort study included Japanese RA patients who started infliximab (n=412, 636.0 patientyears (PY)), etanercept (n=442, 765.3 PY), or tocilizumab (n=168, 206.5 PY) as the first biological therapy after their enrolment in the Registry of Japanese Rheumatoid Arthritis Patients for Long-term Safety (REAL) database. Drug retention rates were calculated using the Kaplan-Meier method. To compare risks of drug discontinuation due to AE for patients treated with these biological agents, the Cox proportional hazard model was applied. Results: The authors found significant differences among the three therapeutic groups in demography, clinical status, comorbidities and usage of concomitant drugs. Development of AE was the most frequent reason for discontinuation of biological agents in the etanercept and tocilizumab groups, and the second most frequent reason in the infliximab group. Discontinuation due to good control was observed most frequently in the infliximab group. Compared with etanercept, the use of infliximab (HR 1.69; 95% CI 1.14 to 2.51) and tocilizumab (HR 1.98; 95% CI 1.04 to 3.76) was significantly associated with a higher risk of discontinuation of biological agents due to AE. Conclusions: Reasons for discontinuation are significantly different among biological agents. The use of infliximab and tocilizumab was significantly associated with treatment discontinuation due to AE compared with etanercept.
URI: http://hdl.handle.net/10069/30709
ISSN: 00034967
DOI: 10.1136/annrheumdis-2011-200838
Rights: © 2013 BMJ Publishing Group Ltd & European League Against Rheumatism. All rights reserved.
Type: Journal Article
Text Version: publisher
Appears in Collections:Articles in academic journal

Citable URI : http://hdl.handle.net/10069/30709

All items in NAOSITE are protected by copyright, with all rights reserved.

 

Valid XHTML 1.0! Copyright © 2006-2015 Nagasaki University Library - Feedback Powerd by DSpace